Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sage Drug Could Help Take Stigma Out Of Postpartum Depression

Executive Summary

SAGE Therapeutics Inc. could offer the one in eight new mothers suffering from postpartum depression (PPD) freedom from the overwhelming condition with the first-ever drug to specifically treat PPD if the rapid and durable response to SAGE-547 in a small Phase II clinical trial holds up in future studies.

Advertisement

Related Content

Sage Therapeutics on PRIME, Partnerships and Pricing For Its PPD First
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Sage Burned By Short Report
JPM Parting Shots: Milestones Ahead For Prothena, Sage, Aimmune, UniQure

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC096892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel